These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 27567724)

  • 1. Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Oct; 31():161. PubMed ID: 27567724
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "The impact of bilingualism on brain structure and function in Huntington's disease" [Park. Relat. Disord. 60C (3783) (2019) 92-97].
    Kulisevsky J
    Parkinsonism Relat Disord; 2020 Dec; 81():157. PubMed ID: 33137619
    [No Abstract]   [Full Text] [Related]  

  • 4. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease.
    Hobbs NZ; Pedrick AV; Say MJ; Frost C; Dar Santos R; Coleman A; Sturrock A; Craufurd D; Stout JC; Leavitt BR; Barnes J; Tabrizi SJ; Scahill RI
    Mov Disord; 2011 Aug; 26(9):1684-90. PubMed ID: 21557312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes" [Parkinsonism Relat. Disord. 21(3) (2015) 231-235].
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2016 Oct; 31():162. PubMed ID: 27575745
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy" [Parkinsonism Relat. Disord. 35 (2017) 88-91].
    Goldstein DS; Sullivan P; Holmes C; Mash DC; Kopin IJ; Sharabi Y
    Parkinsonism Relat Disord; 2017 Jun; 39():95. PubMed ID: 28392299
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Prevalence and functional impact of parkinsonian signs in older adults from the Good Aging in Skåne study" [Parkinsonism Relat. Disord. 111 (2023)].
    Algotsson C; Rosso A; Elmståhl S; Siennicki-Lantz A
    Parkinsonism Relat Disord; 2023 Aug; 113():105485. PubMed ID: 37308400
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma melatonin is reduced in Huntington's disease.
    Kalliolia E; Silajdžić E; Nambron R; Hill NR; Doshi A; Frost C; Watt H; Hindmarsh P; Björkqvist M; Warner TT
    Mov Disord; 2014 Oct; 29(12):1511-5. PubMed ID: 25164424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Brain Correlates of Neuropsychiatric Symptoms in Presymptomatic Huntington's Disease: The IMAGE-HD Study.
    Poudel GR; Driscoll S; Domínguez D JF; Stout JC; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    J Huntingtons Dis; 2015; 4(4):325-32. PubMed ID: 26756589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
    Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
    Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical inhibitory deficits in premanifest and early Huntington's disease.
    Philpott AL; Cummins TDR; Bailey NW; Churchyard A; Fitzgerald PB; Georgiou-Karistianis N
    Behav Brain Res; 2016 Jan; 296():311-317. PubMed ID: 26416671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation between decision-making under risk and decision-making under ambiguity in premanifest and manifest Huntington's disease.
    Adjeroud N; Besnard J; Verny C; Prundean A; Scherer C; Gohier B; Bonneau D; Massioui NE; Allain P
    Neuropsychologia; 2017 Aug; 103():87-95. PubMed ID: 28712946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum to "Sexual dysfunction in patients with multiple sclerosis" [Mult. Scler. Relat. Disord. 2 (2) (2013) 117-123].
    Orasanu B; Frasure H; Wyman A; Mahajan ST
    Mult Scler Relat Disord; 2013 Jul; 2(3):259. PubMed ID: 25877734
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Cardiovascular autonomic dysfunction in multiple sclerosis: A meta-analysis" [Mult. Scler. Relat. Disord. 4 (2015) 104-111].
    Racosta JM; Sposato LA; Morrow SA; Cipriano L; Kimpinski K; Kremenchutzky M
    Mult Scler Relat Disord; 2015 Jul; 4(4):385. PubMed ID: 26195062
    [No Abstract]   [Full Text] [Related]  

  • 16. Postural limits of stability in premanifest and manifest Huntington's disease.
    Medina LD; Pirogovsky E; Salomonczyk D; Goldstein J; Panzera R; Gluhm S; Simmons R; Corey-Bloom J; Gilbert PE
    J Huntingtons Dis; 2013; 2(2):177-84. PubMed ID: 25063514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to "Impaired eye blink classical conditioning distinguishes dystonic patients with and without tremor" [Park. Relat. Disord. 31 (2016) 23-27].
    Antelmi E; Di Stasio F; Rocchi L; Erro R; Liguori R; Ganos C; Brugger F; Teo J; Berardelli A; Rothwell J; Bhatia KP
    Parkinsonism Relat Disord; 2017 Feb; 35():102. PubMed ID: 27989567
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
    Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
    Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum to "Does Natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion" [Multiple Scler. Relat. Disord. 2 (4) (2013) 385-387].
    Sharma K; Ballham SA; Inglis KE; Renowden S; Cottrell DA
    Mult Scler Relat Disord; 2014 Jan; 3(1):136-7. PubMed ID: 25877985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.